€4.5 Million Grant Awarded for Personalized Medicine Project

MUNICH, Dec. 11, 2024 — HMNC Brain Health, a clinical-stage biopharmaceutical company specializing in precision psychiatry, is part of a consortium that has secured a €4.5 million grant from the Austrian Research Promotion Agency (FFG). The three-year grant, awarded through the COMET (Competence Centers for Excellent Technologies) program, involves the Austrian Institute of Technology, Danube Private University, and other partners.

The funding will support the continuation of the “Personalized Medicine Enabled by Intelligent Sensing Systems” (PI-SENS) project. PI-SENS research integrates fundamental and applied research, technology development, and product innovation.

HMNC Brain Health will utilize the grant to analyze data from its ongoing OLIVE trial, a randomized, double-blind, placebo-controlled study involving over 300 patients with Major Depressive Disorder (MDD). This analysis will enhance the company’s research and development efforts in precision psychiatry. The OLIVE trial is part of the Nelivabon program, which focuses on BH-200, a vasopressin V1b receptor antagonist aimed at treating MDD patients with HPA-axis dysfunction.

Professor Dr. Christoph Kleber of Danube Private University stated: “The COMET Project aims to significantly address growing healthcare challenges nationally and internationally. PI-SENS will provide crucial expertise in innovative technology to establish a personalized health and prevention system.”

Dr. Hans Eriksson, Chief Medical Officer of HMNC Brain Health, commented: “As a PI-SENS partner, we will contribute significantly to research with the potential to benefit millions affected by Major Depressive Disorder. Personalized medicine is the future of mental healthcare, and this collaboration with leading institutions will help translate lab discoveries into real-world applications.”

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH), based in Munich, Germany, is a global biopharma company developing personalized therapies for Major Depressive Disorder using predictive companion diagnostics to improve remission rates. Operating in Germany and the U.S., the company is supported by prominent family offices and healthcare investors.

Media Contact (U.S.):
Anne Donohoe
(732) 620-0033
hmncbrain@kcsa.com